We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

Ro said it will provide access to single-dose vials of Eli Lilly’s weight-loss drug Zepbound to patients with obesity ... Always ahead of the curve, HCG is spearheading the charge to turn scientific ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.

1 The research firm reached its conclusion based on a recent study that suggests that Zepbound may be more effective at promoting weight loss than Wegovy. The findings also took into consideration ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...

Sleep apnea causes people to stop and start breathing repeatedly Zepbound is first drug approved by FDA to help treat it Two studies found that those who used it saw reduction in apnea events ...